Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | BPTF | Q12830 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957413 | 1.00 | IRAK4 (0.42) | IRAK4PIM1PIM2BACE1TRIM33 | |
| Trifluoroacetic Acid SCHEMBL3965086 | 0.93 | HRH4 (0.40) | IRAK4PIM1PIM2TRIM33GFER | |
| SCHEMBL5128320 | 0.88 | IRAK4 (0.43) | IRAK4PIM1PIM2FLT3 | |
| SCHEMBL5131504 | 0.84 | IRAK4 (0.42) | IRAK4PIM1PIM2KHKMAPK8 | |
| SCHEMBL5131501 | 0.84 | IRAK4 (0.42) | IRAK4PIM1PIM2KHKMAPK8 | |
| SCHEMBL5132442 | 0.84 | IRAK4 (0.43) | IRAK4PIM1PIM2KHKMAPK8 | |
| SCHEMBL5132445 | 0.84 | IRAK4 (0.43) | IRAK4PIM1PIM2KHKMAPK8 | |
| Hydrochloric Acid SCHEMBL5128561 | 0.84 | IRAK4 (0.41) | IRAK4PIM1PIM2KHKMAPK8 | |
| Hydrochloric Acid SCHEMBL5128563 | 0.84 | IRAK4 (0.41) | IRAK4PIM1PIM2KHKMAPK8 | |
| Hydrochloric Acid SCHEMBL3961216 | 0.83 | IRAK4 (0.43) | IRAK4PIM1PIM2KHKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | claimed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | claimed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | claimed |
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | SCN1A, SCN3A, SCN1B | IRAK4 1483/4885PIM1 4321/4885PIM2 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.